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Recent studies have highlighted the involvement of rare (<1% frequency) copy-number variations and point mutations in the genetic
etiology of autism spectrum disorder (ASD); these variants particularly affect genes involved in the neuronal synaptic complex. The
SHANK gene family consists of three members (SHANK1, SHANK2, and SHANK3), which encode scaffolding proteins required for the
proper formation and function of neuronal synapses. Although SHANK2 and SHANK3 mutations have been implicated in ASD and
intellectual disability, the involvement of SHANK1 is unknown. Here, we assess microarray data from 1,158 Canadian and 456 European
individuals with ASD to discover microdeletions at the SHANK1 locus on chromosome 19. We identify a hemizygous SHANK1 deletion
that segregates in a four-generation family in which male carriers—but not female carriers—have ASD with higher functioning. A de
novo SHANK1 deletion was also detected in an unrelatedmale individual with ASD with higher functioning, and no equivalent SHANK1
mutations were found in >15,000 controls (p ¼ 0.009). The discovery of apparent reduced penetrance of ASD in females bearing in-
herited autosomal SHANK1 deletions provides a possible contributory model for the male gender bias in autism. The data are also infor-
mative for clinical-genetics interpretations of both inherited and sporadic forms of ASD involving SHANK1.Autism is the prototypic form of a group of conditions,
also known as ‘‘autism spectrum disorders’’ (ASDs [MIM
209850]), that share common characteristics (impairments
in socialization and communication and a pattern of repet-
itive interests and behaviors) but differ in developmental
course, symptom pattern, and cognitive and language
abilities. Other ASD subtypes include Asperger disorder
(which has less severe language and cognitive deficits)
and pervasive developmental disorder not otherwise spec-
ified (PDD-NOS; subthreshold symptoms and/or later
onset). Subclinical forms of ASD are often characterized
as the broader autism phenotype (BAP).1 Twin and family
studies provide evidence of the importance of complex
genetic factors in the development of both sporadic and
inherited forms of idiopathic autism. An enigma in ASD
is the 4:1 male to female gender bias, which might rise to
11:1 when Asperger disorder is considered.21The Centre for Applied Genomics and Program in Genetics and Genome
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The AmRare copy-number variations (CNVs) and sequence-level
mutations have been identified as etiologic factors
in ASD.3–5 De novo CNVs are observed in 5%–10% of
ASD cases.6–10 A relative enrichment of CNVs disrupting
synaptic complex genes11,12 is observed, and NLGN3
(MIM 300336), NLGN4 (MIM 300427),13 NRXN1 (MIM
600565),14 NRXN3 (MIM 600567),15 SHANK2 (MIM
603290),9,16,17 and SHANK3 (MIM 606230)18–20 have
been identified as highly penetrant susceptibility loci for
ASD and intellectual disability (ID). The SHANK gene
family,21,22 which also includes SHANK1 (MIM 604999),
encodes scaffolding proteins that localize to postsynaptic
sites of excitatory synapses in the brain.
We describe seven individuals with deletions involving
SHANK1. Four male cases have ASD with higher function-
ing or the BAP and are from amultigenerational family (see
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Figure 1. Pedigree of Family 1
Pedigree of a multigenerational family carrying a rare CNV that deletes one copy of SHANK1. Individuals with ASD and BAP are indicated
by filled symbols and striped symbols, respectively. The proband is indicated by an arrow. ‘‘WT’’ indicates individuals that have the
typical copy number of two at the SHANK1 locus, and ‘‘NA’’ indicates the unavailability of DNA.an unrelated fifth ASD male case has a de novo deletion at
the same locus (see family 2 in Figure S1, available online),
and two female individuals from family 1 (Figure 1) have
the SHANK1 deletion but no ASD or BAP.
The ASD dataset examined in this study was composed
of 1,158 unrelated Canadian individuals (898 males and
260 females) and 456 unrelated European individuals
(362 males and 94 females). All individuals with ASD
were diagnosed by expert clinicians on the basis of the
Autism Diagnostic Interview-Revised (ADI-R) and/or the
Autism Diagnostic Observation Schedule (ADOS).23
Canadian cases were recruited from five different sites:
The Hospital for Sick Children, Toronto, Ontario; McMas-
ter University, Hamilton, Ontario; Memorial University
of Newfoundland, St. John’s, Newfoundland; University
of Alberta, Edmonton, Alberta; and the Montreal Chil-
dren’s Hospital of the McGill University Health Centre,
Montreal, Quebec. The European ASD subjects were re-
cruited by the PARIS (Paris Autism Research International
Sibpair) study and several other sites at specialized clin-
ical centers dispersed in France, Sweden, Germany,
Finland, and the UK. In Sweden, for some cases, the
Diagnostic Interview for Social and Communication
Disorders (DISCO-10) was applied instead of the ADI-R.
The ID dataset consisted of 185 mostly French Canadians
(98 males and 87 females) and 155 German nonsyn-
dromic ID cases (93 males and 62 females). Further
descriptions of these datasets and the assessment proce-
dures used are available elsewhere.16,24 Approval was
obtained from the research ethics boards at The Hospital
for Sick Children (Toronto) and McMaster University for880 The American Journal of Human Genetics 90, 879–887, May 4, 2the study, and informed written consent was obtained
from all participants.
For the assessment of the presence of CNVs on a
genome-wide scale, DNA from the Canadian ASD dataset
was genotyped at The Centre for Applied Genomics, Tor-
onto with one of three high-resolution microarray plat-
forms: Affymetrix GeneChip SNP 6.0, Illumina Infinium
1M single SNP, or Agilent SurePrint G3 Human CGH
(comparative genomic hybridization) 1x1M. The probe
coverage of these platforms at the SHANK1 region is
shown in Figure S2. CNVs were analyzed with published
methods.9,25,26 Briefly, CNV calling was performed with
a multialgorithm approach that used at least two different
algorithms for the three array platforms: Affymetrix 6.0
(Birdsuite, iPattern, and Genotyping Console), Illumina
1M (PennCNV, QuantiSNP, and iPattern), and Agilent
CGH 1x1M (DNA Analytics and CBS from DNAcopy
package). Subsequent analyses focused on those CNVs
spanning five or more array probes and detected by at least
two algorithms. Independent validation of the deletion
at the SHANK1 locus in family 1 was performed with
SYBR-Green-based real-time quantitative PCR (qPCR), for
which two independent primer pairs were placed at the
SHANK1 locus and the FOXP2 (MIM 605317) locus as
a negative (diploid) control (Figure S3). All primers used
in qPCR validation and breakpoint mapping are listed in
Table S1.
Using the Illumina Human 1M-Duo BeadChip, we geno-
typed DNA from the European ASD dataset at the Centre
National de Ge´notypage at the Institut Pasteur. CNVs
were analyzed with previously published methods.9012
Table 1. Clinical Description of Individuals Carrying SHANK1 Deletion
Clinical Details
Diagnosis IQa Languageb Adaptive Behaviorc Brain Imaging
Family 1d
III-5 (male) ASDe: Asperger disorder
(ADI-R and ADOS-4)
and anxiety
Leiter-R: brief
NVIQ ¼ 83
(13th % ile; LA)
OWLS: TL ¼ 68
(2nd % ile; delay)
VABS-I: ABC ¼ 52
(<1st % ile), COM ¼ 43
(<1st % ile), DLS ¼ 63
(1st % ile), and SOC ¼ 65
(1st % ile); he currently
takes olanzapine and
paroxetine for the
anxiety disorder
–
I-1 (male) BAP: shy, reserved,
and reluctant to
approach people;
amassed a large stamp
collection; deceased
– – – –
IV-1 (male) ASD: Asperger disorder
(ADI-R; SRS: 68T/mild
to moderate)
WASI: VIQ ¼ 114
(82nd % ile; HA)
and PIQ ¼ 86
(18th % ile; LA)
OWLS: TL ¼ 93, RL ¼ 82
(12th % ile), and EL ¼ 107
(68th % ile)
VABS-II: ABC ¼ 85
(16th % ile), COM ¼ 92
(30th % ile), DLS ¼ 85
(16th % ile), and SOC ¼ 85
(16th % ile)
–
PPVT: RV ¼ 97 (42nd % ile)
IV-3 (male) ASD: Asperger disorder
(ADI-R and ADOS-3)
WPPSI: FSIQ ¼ 89
(23rd % ile; LA),
VIQ ¼ 89 (23rd % ile),
and PIQ ¼ 91
(27th % ile)
OWLS: TL ¼ 80 (9th % ile),
RL ¼ 78 (7th % ile),
and EL ¼ 86 (18th % ile)
VABS-II: ABC ¼ 86
(18th % ile), COM ¼ 91
(27th % ile), DLS ¼ 89
(23rd % ile), SOC ¼ 85
(16th % ile), and
MOT ¼ 91 (27th % ile)
–
PPVT: RV ¼ 91 (27th % ile)
II-4 (female) non-ASD and non-BAP;
anxiety and shyness
– – – –
III-2 (female) non-ASD and non-BAP;
social anxiety disorder
and generalized anxiety
disorder; shy as a child
– PPVT: RV ¼ 111 (77th % ile) – –
Family 2f
II-1 (male) ASD with higher
functioning
(ADI-R; CARS:
mild autism)
WISC: FSIQ ¼ 115
(84th % ile; HA),
VIQ ¼ 120 (93rd % ile),
and PIQ ¼ 100
(50th % ile) (VIQ > PIQ)
– – PET: mild
hyperfusion
temporal left
Refer to pedigrees in Figure 1 (family 1) and Figure S1 (family 2). The following abbreviations are used: IQ, intelligence quotient; ASD, autism spectrum disorder; %
ile, percentile; and PET, positron emission tomography.
aIQ was measured with an age-appropriate Weschler scale (WPPSI, Wechsler Preschool and Primary Scale of Intelligence; WISC, Wechsler Intelligence Scale for
Children; or WASI, Wechsler Abbreviated Scale of Intelligence). Standard scores and percentiles are presented for full-scale IQ (FSIQ), verbal IQ (VIQ), and/or
performance IQ (PIQ). FSIQ is not a valid estimate of IQ when significant discrepancy exists between VIQ and PIQ. Leiter International Performance Scale-Revised
(Leiter-R) is a measure of nonverbal IQ (NVIQ) only. Percentile classifications are the following: very superior (VS; >98th % ile), superior (S; 91st–97th %
ile), high average (HA; 75th–90th % ile), average (A; 25th–74th % ile), low average (LA; 9th–24th % ile), borderline (B; 2nd–8th % ile), and extremely low
(EL; <2nd % ile).
bLanguage was measured with the Oral and Written Language Scales (OWLS). Standard scores and percentiles are presented for total language (TL), receptive
language (RL), and/or expressive language (EL). Language was rated as nonverbal, average, or delayed (%16th % ile). The Peabody Picture Vocabulary Test
(PPVT-4th edition) measured receptive vocabulary (RV).
cAdaptive Behavior was measured with the Vineland Adaptive Behavior Scales (VABS). Standard score and percentiles are presented for adaptive behavior
composite (ABC), communication (COM), daily living skills (DLS), socialization (SOC), and motor (MOT; only for children 7 years old or younger).
dLanguage details for IV-2 (female) in family 1 are the following: (OWLS) RL = 87 (19th % ile) and EL = 108 (70th % ile) and (PPVT) RV = 103 (58th % ile).
eThe autism-spectrum diagnosis is based on the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS; one of four
possible modules is administered on the basis of age and language level). In some cases, the Social Responsiveness Scale (SRS) was administered, and reported
T-scores represent average skills (%59T), mild to moderate concerns (60T–75T), or a severe range (76T or higher). Also, the diagnosis for II-1 in family 2 was based
on the Childhood Autism Rating Scale (CARS).
fII-3 (female) in family 2 was diagnosed with ASD (ADI-R; CARS: mild autism). Her WIPPSI IQ details are the following: PIQ = 99 (50th% ile) and VIQ = nonfunctional
language.Validation of the array CNV calls was performed with
qPCR in a similar way as described above; two independent
primer pairs were placed at the SHANK1 locus and at the
exon 18 locus of SHANK1 as a negative (diploid) control
(Figure S3).The AmWe initially identified a hemizygous microdeletion in
chromosomal region 19q13.33 in ASD proband III-5
from the Canadian cohort (see family 1 in Table 1 and
Figure 1). The deletion, which was determined to be
63.8 kb, eliminated exons 1–20 of SHANK1 and theerican Journal of Human Genetics 90, 879–887, May 4, 2012 881
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Figure 2. Rare Deletions at SHANK1 Locus in the Two ASD-Affected Families
Chromosomal position of rare deletions of SHANK1 and adjacent genes in ASD. The accurate coordinates for family 1 were mapped by
sequencing across the breakpoints and are Chr 19: 55,872,189–55,935,995 (hg18). The de novo deletion of family 2 was detected by
microarray and has coordinates Chr 19: 55,808,307–55,871,709 (hg18).neighboring CLEC11A (MIM 604713), which codes for
a growth factor for primitive hematopoietic progenitor
cells (Figure 2). Subsequent genotyping in family 1
revealed that the deletion was also present in males I-1,
IV-1, and IV-3 as well as in females II-4 and III-2 (Figure 1).
At 16 years of age, proband III-5 was first assessed by
a child psychiatrist and was initially given a clinical diag-
nosis of PDD-NOS. Starting at an early age, there was
evidence of impairment in social communication, but
there were not enough repetitive stereotyped behaviors
for a diagnosis of autism or Asperger disorder. The ADI-R
and the ADOS were completed when the proband was 25
years old. The ADI-R indicated that the parents first
became concerned when their son was 12–24 months
old, a period during which III-5 engaged in repetitive
play and speech. He spoke in single words at 24 months
of age and spoke in phrases by 36 months of age. He has
never lost language or other skills. He has no history of
echolalia, pronoun reversal, or neologisms. His eye contact
has always been poor, and he has persistently lacked social
smiling, facial affect, joint attention, and empathy. His
interests during childhood and adolescence included video
games, movies, and sports cards. He graduated from high
school, and now, at age 32, he lives independently and
works in a sheltered workshop. When III-5 was 25 years
old, the ADI-R and ADOS diagnosed him with autism
according to the cut-offs, but his current best-estimate
diagnoses are that of Asperger disorder (in view of the
normal language development) and a separate anxiety
disorder; anxiety disorders are common comorbid condi-
tions but are not considered part of the ASD clinical
spectrum.
An extensive battery of questionnaires and tests were
administered to III-5’s parents, and both scored in the
typical range. His mother (II-4) has exhibited anxiety and
shyness for most of her life but would not be considered
to have ASD or BAP. His 40-year-old sister (III-2) is married
with one son (IV-1) with Asperger disorder, a neurotypical
daughter (IV-2), and a son (IV-3) with ASD. III-2 completed
university andworked as a school teacher for years. She has882 The American Journal of Human Genetics 90, 879–887, May 4, 2a diagnosis of social anxiety and a generalized anxiety
disorder for which she has taken antianxiety medication.
Assessment by interview and questionnaire indicated
that she was typical for all measures and did not show
evidence of ASD or the BAP.
III-5’s maternal grandfather (I-1) passed away when he
was 95 years old. Little is known about his childhood
other than that he had difficulty in school. Throughout
his adult life, he had been quiet and withdrawn. He did
not develop close relationships. He was a truck driver
and spent most of his time away from home. There was
no history of psychiatric illness. He was an avid stamp
collector but did not use this interest to engage in social
interactions. His children were interviewed so that a
diagnosis of ASD could be determined; based on this
interview, our clinical impression is that he most likely
had, at the very least, the BAP or, possibly, high-func-
tioning ASD, which could not be determined under the
circumstances.
IV-1 was clinically diagnosed with Asperger disorder
when he was 8 years old. He was born by cesarean section
10 days late. Early developmental milestones were within
normal limits. When he was 3 years old, his parents
detected developmental differences by noting that he
was not interested in other children and was preoccupied
with objects. He had an encyclopedic knowledge of cars.
He would approach other children but tended to play
beside them and became upset with changes in routine.
He exhibited difficulties with eye contact and under-
standing social cues and rules.
Additional assessments were conducted when he was
10 years old. He met all the cut-offs for an autistic disorder
on the ADI-R except for the nonverbal total. The ADOS
scores were below the cut-off for a diagnosis of ASD
because of his strengths in the communication domain.
Descriptive gestures were present but were vague and
infrequent, accounting for his communication score of
1 (the cut-off is 2). Impairments in reciprocal social inter-
action continued to be evident. His score on the perfor-
mance intelligence quotient (IQ) component (score ¼ 86)012
of psychometric testing was significantly lower than his
score on the verbal IQ subtests (score ¼ 114). IV-1 qualified
for a diagnosis of Asperger disorder.
Individual IV-3 was first evaluated when he was 3 years
old. When he was 18 months old, his parents became con-
cerned because he was not talking. He developed single
words at 24 months. He communicated by leading his
parents by the hand and exhibited repetitive behaviors.
He did not offer comfort or empathy and did not initiate
social interaction, although he would play with his
parents. Certain noises such as the washing machine or
the toilet flushing would bother him; he became upset if
his mother had her hair down or a jacket unzipped.
Assessment when he was 5 years and 8 months old indi-
cated that he was positive on the ADI-R for autism and for
ASD on the ADOS. He had made good progress in social
interaction and language. His expressive language con-
sisted of short sentences and phrases and some echoed
speech and mild articulation difficulties. His IQ and
expressive and receptive language scores were in the low-
average range, leading to a best-estimate diagnosis of
Asperger disorder.
In separate microarray experiments examining 456 ASD-
affected individuals from Europe, we identified a 63.4 kb
hemizygous CNV in individual F2-II-1 from family 2; this
CNV deleted the last three exons of SHANK1 and the entire
centromeric synaptotagmin-3 (SYT3 [MIM 600327]) gene,
which plays a role in Ca2þ-dependent exocytosis of
secretory vesicles (Table 1, Figure 2). Haplotype analysis
revealed that the deletion resided on the chromosome
originating from the mother (who was shown to carry
two copies of SHANK1), so it was presumed to be a de
novo event (Figure S1). The deletion was not in F2-II-3.
Male individual F2-II-1 (Table 1 and Figure S1) was the
first child born to a 20-year-old mother. He has a younger
maternal half-sister (F2-II-3) with autism and mild ID. F2-
II-1 was born two months before term. Developmental
abnormalities were identified during his first year. He did
not babble, made no eye contact, and refused to be
touched. He started to walk at two years of age, but his
motor coordination was poor. He started to talk at 2.5 years
of age, which astonished the parents because until then, he
had been extremely quiet. He developed a formal, pedantic
style of speech with abnormal prosody. He was uninter-
ested in other children. He repeated routines and rituals
and accumulated facts on certain subjects such as
astronomy. When upset, he flapped his hands or moved
his body in a stereotypic fashion. Lately, he has had
periods of depression. His IQ is in the normal range and
shows that he has good verbal ability. The best estimate
diagnosis for F2-II-1 is autism with higher functioning.
No deletion equivalent to those described in families 1
or 2 was observed in 15,122 control individuals. These
controls included 2,026 healthy individuals from the
Children’s Hospital of Philadelphia,27 2,493 controls geno-
typed at the University of Washington,28 and 10,603
population-based controls8,9,25 whose microarray dataThe Amwere analyzed by our group. This latter dataset included
1,123 controls from northern Germany,29 1,234 Canadian
controls from Ottawa,30 1,120 population controls from
Ontario,31 1,056 HapMap samples,32 4,783 controls from
the Wellcome Trust Case Control Consortium,33 and
1,287 controls recruited by the Study of Addiction:
Genetics and Environment consortium.34 Control individ-
uals were predominantly of European ancestry, which was
comparable to the ancestry of the ASD subjects. We also
examined the Database of Genomic Variants35,36 for
previously reported CNVs at the SHANK1 locus. One
study37 reported an unvalidated 109.1 kb deletion encom-
passing the entire SHANK1 gene in a Japanese female
HapMap individual (NA18942). We obtained this DNA
sample and performed qPCR by using two independent
primer pairs at the SHANK1 locus; we were unable to
confirm the deletion, indicating that it was a false-positive
call (Figure S3).
The frequency of deletions at the SHANK1 locus is sig-
nificantly higher in ASD cases than in controls (2/1,614
cases versus 0/15,122 controls; Fisher’s Exact test two-
tailed p ¼ 0.009). No other obvious potentially etiologic
CNV was observed in any of the individuals with ASD in
families 1 or 2 (Tables S2 and S3). Therefore, at this resolu-
tion of analysis, the rare deletions of common segments of
SHANK1 were the only common events observed between
the two unrelated ASD families.
To test for potential damaging sequence-level mutations
in SHANK1, we used Sanger sequencing to examine all 23
exons and splice sites in 509 unrelated ASD (384 male
and 125 female) and 340 ID (191 males and 149 females)
individuals. The rationale for SHANK1mutation screening
of ASD and ID cases arises from our previous observation of
rare truncating nonsense and/or frameshift mutations in
SHANK216 and SHANK318,19,38 in both of these disorders.
We used Primer3 software v.0.4.0 to design PCR primers.
We performed PCRs by using standard conditions, and
we purified and sequenced products directly by using the
BigDye Terminator sequencing (Applied Biosystems, Foster
City, CA, USA). Variant detection was performed with Seq-
Scape software from Applied Biosystems. We validated
variants detected in the cases but not previously reported
in the Single Nucleotide Polymorphism Database (dbSNP)
build 130 by resequencing samples from the proband,
both parents, and the siblings when available. All primers
used for Sanger sequencing of SHANK1 and PCDHGA11 are
listed in Table S4.
We detected 26 rare missense variants in 23 ASD and
seven ID cases, which were not found in dbSNP build
130 or in 285 control individuals from the Ontario general
population (Table S5 and Figures S4 and S5). However, only
two of these missense variants (c.877 G>A [p.Asp293Asn]
in families 5 and 6 and c.2207 G>A [p.Arg736Gln] in
family 9) are predicted to be damaging on the basis of their
alteration of highly conserved residues within the ANK
and PDZ domains, respectively. Although they occur in
males with ASD, both variants are also found in non-ASDerican Journal of Human Genetics 90, 879–887, May 4, 2012 883
(or BAP) fathers. No significant mutation was found on the
nondeleted allele of proband III-5.
We also conducted whole-exome sequencing in individ-
uals III-5 and IV-3 from family 1 to search for potential
mutations in other genes (Table S6). We performed target
enrichment by utilizing the Agilent SureSelect 50Mb
Human All Exon kit (Agilent Technologies, Santa Clara,
CA, USA), and we conducted paired-end sequencing on
a Life Technologies SOLiD5500XL (Life Technologies,
Foster City, CA, USA) platform. Protocols for sequencing
and target capture followed specifications from the manu-
facturers.
A nonsense mutation (Tyr313*) predicted to introduce
a stop codon in the PCDHGA11 prodocadherin gene in
chromosomal region 5q31.3 was identified. PCDHGA11
is a member of the protocadherin gamma gene cluster
thought to have an important role in establishing connec-
tions in the brain.39 The nonsense variant in PCDHGA11
(MIM 606298) was validated by Sanger sequencing. The
mutation was found to segregate precisely with the
SHANK1 deletion. Because SHANK1 and PCDHGA11 reside
on different autosomes, we tested for translocation or
transposition and ruled out such linkage (Figure S6). It is
possible that the Tyr313* mutation in PCDHGA11 works
in concert with the SHANK1 deletion to modify (positively
or negatively) the extent of the phenotype or that they are
just randomly cosegregating (a 1/262,144 chance). We
have not detected CNVs or sequence-level mutations in
PCDHGA11 in family 2 or in any other ASD subject exam-
ined. We have also tentatively ruled out the role of the X
chromosome in family 1 given that different X chromo-
somes were observed in ASD males (by comparing SNP
genotypes), and no pathogenic CNV, mutation, or genetic
linkage was observed at the X chromosome (Figure S7). The
PCDHGA11 and SHANK1 loci at 5q31.3 and 19q13.33,
respectively, represented two of five chromosomal regions
in which maximal linkage was detected (Figure S7). No
other obvious damaging sequence mutations or CNVs
were found in genes in the other three putative linkage
regions.
We provide here a description of hemizygous deletions
of SHANK1 in ASD. Such findings have, perhaps, been
anticipated given that mutations leading to haploinsuffi-
ciency of SHANK2 and SHANK3 have been previously
described in ASD. The striking segregation of ASD in only
male SHANK1-deletion carriers in family 1 represents, to
our knowledge, the first example of autosomal sex-limited
expression in ASD.40 Our finding of an unrelated ASD-
affected male carrying an independent de novo deletion
of SHANK1 supports our interpretation that the SHANK1
CNV segregating in family 1 is indeed the primary etiologic
event leading to ASD. Additional case reports of other
multigenerational families will be required for substanti-
ating our findings of gender-influenced autosomal pene-
trance differences at the SHANK1 locus in ASD.
Our data indicate that SHANK1 deletions are associated
with ASD with higher functioning in males. Insofar as all884 The American Journal of Human Genetics 90, 879–887, May 4, 2affected males have an IQ in the typical range and have
good verbal ability (with a lack of clinically significant
language delay), they would also qualify for a diagnosis
of Asperger disorder. The one other male (individual I-1)
had a diagnosis of the BAP (although this diagnosis was
based only on retrospective reports, which preclude the
potential for an ASD diagnosis). The female carriers do
not show evidence of ASD or the BAP but have suffered
from anxiety, which is considered to be an unrelated
phenotype to ASD (Table 1). It is surprising that, compared
to other studies of inherited CNVs,3 this pedigree
shows little variability in clinical features among affected
individuals.
We note that the neuronal genes PCDHGA11 and SYT3
could also contribute to aspects of the ASD phenotype in
families 1 and 2, respectively. Moreover, subtler muta-
tions,41,42 or combinations of mutations,17 might also be
involved. The latter possibility might be particularly rele-
vant given early findings that suggest potential multigenic
effects including SHANK2 in ASD risk.17 Paternal silencing
or imprinting of SHANK1, as well as potential transmission
distortion with respect to cosegregation of SHANK1 and
PCDHGA11, also needs to be considered, but at least for
the former, there is insufficient evidence for this.43
Consistent with our findings in humans, Shank1-null
murines have deficits in several elements of social com-
munication and developmental milestones.44 They also
exhibit increased anxiety-related behavior and impaired
memory.45 Shank2 and Shank3 offer immature excitatory
synapses with unique properties that facilitate synapto-
genesis. Shank1 has the important, but perhaps less
critical, structural role of ‘‘consolidating’’ novel synaptic
contacts via capping Shank2 and Shank3.22,46 Mutations
in SHANK1 might be predicted generally to have less of
an impact on synapsemorphology and stability and, there-
fore, a less severe phenotype than do similar alterations in
SHANK2 or SHANK3. Given that SHANK2 and SHANK3
mutations are observed in ID16,38 and schizophrenia
(MIM 181500),47 it is possible that SHANK1 mutations
will also be similarly found in other brain disorders.
There are currently three prevailing theories explaining
the gender bias in autism. The ‘‘extreme brain’’ theory
proposes that autistic behaviors are an exaggeration of
typical male personality traits.48 A second theory suggests
that given the established genetic basis of autism, it is
possible that the sex bias lies in the sex chromosomes.
Rare mutations in some X-linked genes such as NLGN3
and NLGN413 and the PTCHD1 locus (MIM 300828)49
have been shown to confer risk to idiopathic ASD in
male carriers. A third theory50 posits a sex-specific
multiple-threshold model in which females need to carry
more genetic liability than males in order to develop
ASD. Some protective factor must exist to account for
that higher threshold. Our discovery of rare autosomal
SHANK1 deletions associated with ASD or the BAP that is
limited to males provides further evidence of the existence
of this protective factor and has significant implications012
for elucidating the molecular basis of sex bias in ASD.
These results will also have immediate relevance for
clinical genetic testing in ASD.Supplemental Data
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